Obicetrapib is an experimental CETP inhibitor that is intended to treat dyslipidemia. In a clinical trial, as an add-on to statins, compared with placebo, it decreased concentrations of LDL-C, apolipoprotein B and non-high-density lipoprotein cholesterol, and increased HDL-C concentration. From Wikipedia
